Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy

INCLUSION CRITERIA:

* Patient and family must agree to return to the clinic up to 8 times within 2 months
* Children ≥ 8 and \<18 years of age at the time of study entry who were previously treated for:
* a hypothalamic tumor
* mid-line brain tumor
* a tumor involving one or both thalami
* craniopharyngioma
* diagnosis of hydrocephalus secondary to a brain tumor or treatment of a brain tumor that required placement of a permanent shunt.
* Off cancer treatment for at least six months
* Proficient in English
* Able to swallow capsules
* Experiencing symptoms of excessive daytime sleepiness (EDS) for at least three months prior to study entry that is not a result of inadequate sleep hygiene or other known medical disorder.
* Negative pregnancy test

EXCLUSION CRITERIA:

* Patients treated with doxorubicin or high dose cyclophosphamide
* History of a clinically significant drug sensitivity to methylphenidate, modafinil, armodafinil or any of their components
* Known cardiac disorders including arrhythmias, hypertension requiring treatment or structural heart disease
* Have taken methylphenidate or modafinil within the last 14 days
* Current/concurrent use of antihistamines, benzodiazepine, anticonvulsants or alcohol
* Clinical diagnosis of major depression, subclinical depression, or anxiety disorder
* History of psychosis or mania
* Patients with suicidal ideation
* Diagnosis with anemia, untreated hypothyroidism, mononucleosis or narcolepsy
* History of substance abuse
* Pregnant or breast feeding
* A total dietary intake of more than 500 mg of caffeine per day (e.g., approximately ten 330 mL cans of soft drinks, five cups of coffee or tea, or 750 g chocolate per day).